Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWeb Index Takes 7 Percent Tumble in September

NEW YORK – The GenomeWeb Index ended a three-month winning streak in September, falling 7 percent as the wider markets took dives of their own.

The index underperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index which fell 4 percent, 5 percent, and 5 percent last month, respectively. The performance of individual stocks in the GenomeWeb Index was largely negative in September, as 32 of the 35 stocks saw losses and only three saw gains.

Quidel led the gainers in September with a 9 percent increase in share price, followed by Genetron (+4 percent) and Thermo Fisher Scientific (+3 percent).

Berkeley Lights led the decliners in September with a 45 percent drop in stock price, followed by Pacific Biosciences and NanoString Technologies, which both lost 18 percent. This was Berkeley Lights' second month in a row leading the decliners. The company's shares dropped 22 percent in August.

Berkeley Lights' stock took a 30 percent tumble in two days mid-September after Scorpion Capital published a short-selling report accusing the company of "fleecing customers and IPO bagholders with a $2 million black box that's a clunker, while insiders and Silicon Valley bigwigs race[d] to dump stock."

The report claimed to contain stories from customers who were "tricked or misled" into buying the company's stock, warned of the company's "looming collapse," and said its product claims and practices "may constitute outright fraud."

Though this report caused the stock to take a very sharp downturn, investment analysts who cover the firm said the company's business proposition remains intact and they expressed optimism about its long-term prospects.

In a note to investors, JP Morgan's Julia Qin reiterated her Overweight rating on Berkeley Lights' shares, writing that she sees "little merit in most of the accusations made in the short report, and we believe the underlying value proposition of Berkeley Lights' Beacon platform stays intact."

Further, Qin added, the company had customers on site the same week the report came out who expressed no concern in reaction to it, and the firm's management remains confident in the path forward.

"While a few visibility questions remain on the newer commercialization models (subscription and partnerships), this will improve over time as the company gains more operating experience with these models," Qin wrote. "We believe the drastic stock reaction since yesterday is way overdone and creates an attractive opportunity to revisit the story."

There didn't seem to be specific reasons for the declines in PacBio or NanoString's shares. Indeed, PacBio had a rather positive September. The company scored a victory in China in a patent dispute against a Taiwanese firm. And Canaccord Genuity initiated coverage of the company's shares with a Buy rating and a 12-month price target of $45.

The declines for both firms may have simply followed from the general stock market declines.

On the side of the gainers, Quidel's stock likely benefited from a $647 million contract awarded by the US Department of Defense to four companies, including Quidel, to purchase over-the-counter SARS-CoV-2 test kits. Quidel's contract was valued at $284.2 million to cover the delivery of 25.6 million tests.

Craig-Hallum analyst Alex Nowak wrote that the US government's recently announced plan to increase point-of-care COVID-19 testing "feeds directly into [Quidel's] strengths," adding that the company "should be in a good position" to supply the demand from the federal government.

Company Ticker 30-Sep-21 31-Aug-21 % change
Adaptive Biotechnologies ADPT 33.99 36.32 -6.42
Agilent Technologies A 157.53 175.47 -10.22
Becton Dickinson* BDX 245.82 251.70 -2.34
Berkeley Lights BLI 19.56 35.56 -44.99
Bio-Rad Laboratories BIO 745.95 804.82 -7.31
Bio-Techne TECH 484.57 499.14 -2.92
Bruker BRKR 78.10 88.31 -11.56
Burning Rock Biotech BNR 17.88 18.63 -4.03
CareDx CDNA 63.37 73.28 -13.52
Castle Biosciences CSTL 66.50 76.73 -13.33
Danaher** DHR 304.44 324.16 -6.08
Exact Sciences EXAS 95.45 104.38 -8.56
Fluidigm FLDM 6.59 7.21 -8.60
Fulgent Genetics FLGT 89.95 91.24 -1.41
Genetron GTH 13.85 13.29 4.21
Guardant Health GH 125.01 127.27 -1.78
Hologic HOLX 73.81 79.15 -6.75
Illumina ILMN 405.61 457.16 -11.28
Invitae NVTA 28.43 29.63 -4.05
Meridian Bioscience VIVO 19.24 20.24 -4.94
Myriad Genetics MYGN 32.29 35.78 -9.75
NanoString Technologies NSTG 48.01 58.20 -17.51
Natera NTRA 111.44 118.43 -5.90
NeoGenomics Laboratories NEO 48.24 48.62 -0.78
Pacific Biosciences PACB 25.55 31.31 -18.40
Personalis PSNL 19.24 21.18 -9.16
PerkinElmer PKI 173.29 184.80 -6.23
Qiagen QGEN 51.68 55.82 -7.42
Quanterix QTRX 49.79 51.05 -2.47
Quidel QDEL 141.15 128.95 9.46
Thermo Fisher Scientific*** TMO 571.33 554.95 2.95
Twist Bioscience TWST 106.97 113.21 -5.51
Veracyte VCYT 46.45 48.11 -3.45
Waters WAT 357.30 414.02 -13.70
10x Genomics TXG 145.58 175.92 -17.25
GenomeWeb Index Average   142.97 152.97 -6.54
         
*BD paid a dividend of $.83 per share on Sept. 8
**Danaher paid a dividend of $.21 per share on Sept. 29
***Thermo Fisher paid a dividend of $.26 per share on Sept. 14
The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.